Sign inJoin waitlistJoin the waitlist

KK

Kari Kendra

Section Chief, Cutaneous Oncology · Ohio State University Hospital

Credentials: · · · ·

History

Cutaneous Oncology Section · Ohio State University Hospital
Present

Medical Oncology
1993–1995
Internal Medicine
1990–1993
Rush Medical College
1986–1990

Research

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine · 2023 · 739 citations
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
New England Journal of Medicine · 2011 · 677 citations
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
Journal of Clinical Oncology · 2013 · 632 citations

William Carson
25 papers
TO
Thomas Olencki
17 papers
Dwight Owen
16 papers
Carolyn Presley
15 papers
Claire Verschraegen
14 papers
GO
Gregory Otterson
14 papers
Mingjia Li
14 papers
RW
Richard Wu
13 papers
Antoni Ribas
12 papers
John Kirkwood
12 papers
Vernon Sondak
12 papers
Bartosz Chmielowski
11 papers

Clinical trials

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Principal investigator · Recruiting · Phase 1, Phase 2
Kari Kendra
2023–2027
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2017–2027
Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 1
Kari Kendra
2014–2018
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Principal investigator · Completed · Phase 2
Kari Kendra
2005–2009